We observed colocalisation between UC risk and an eQTL for PRKCB (PPh4 = 0.95, Supplementary Material S2), which encodes protein kinase C-β, a druggable kinase with inhibitors approved for oncology and already undergoing early-phase clinical trials for IBD. This evidence concerns the gene KCNK3 and inflammatory bowel disease.